Compounded GLP-1 medications - primarily semaglutide and tirzepatide - became a defining feature of the weight management landscape during the period of branded product shortages. For many cash-pay practices, compounded versions made GLP-1 therapy financially accessible to a patient population that could not afford or access Wegovy, Ozempic, Zepbound, or Mounjaro. But the regulatory environment governing these compounds has shifted materially, and providers who are not current on the legal framework are carrying risk that requires active management.
This article covers the legal basis for compounding GLP-1 medications, the critical distinction between 503A and 503B pharmacies, how to evaluate a compounding pharmacy before prescribing from it, the safety considerations specific to compounded GLP-1 products, and the documentation practices that protect providers who choose to continue offering these medications.
THE LEGAL BASIS FOR COMPOUNDING GLP-1 MEDICATIONS
Pharmaceutical compounding in the United States is governed primarily by Section 503A and Section 503B of the Federal Food Drug and Cosmetic Act, as well as state pharmacy board regulations that vary by jurisdiction. Understanding both the federal framework and the specific legal basis on which compounded GLP-1 medications have been permitted is essential for providers prescribing these products.
The shortage exception. During periods when an FDA-approved drug appears on the FDA's drug shortage list, compounding pharmacies have greater latitude to compound copies or near-copies of that drug. Both semaglutide and tirzepatide were on the FDA shortage list for extended periods, which provided the primary legal basis for widespread compounded GLP-1 production during that time.
The shortage status of both semaglutide and tirzepatide has changed as branded product availability has improved. The FDA has taken the position that once a shortage is resolved, the legal basis for compounding that specific drug is substantially narrowed. The FDA has issued guidance and warning letters targeting compounders producing semaglutide and tirzepatide outside of a shortage-based exception, and the enforcement posture has intensified.
Providers should verify the current shortage status of any GLP-1 medication they are prescribing in compounded form, as this status can change and the legal landscape continues to evolve. Staying current requires active monitoring of FDA guidance rather than assuming that what was permissible twelve months ago remains permissible today.
503A VS. 503B: THE DISTINCTION THAT MATTERS
The difference between 503A and 503B pharmacies is one of the most practically important distinctions in compounding pharmacy law - and one that is frequently misunderstood by prescribing providers.
503A pharmacies are traditional compounding pharmacies that compound medications for individual patients based on a valid prescription from a licensed prescriber. They are regulated primarily by state pharmacy boards rather than the FDA. 503A pharmacies may not compound copies of commercially available drugs in anticipation of prescriptions - they are intended to compound for specific identified patients with specific documented clinical needs.
The clinical need requirement is significant in the context of compounded GLP-1s. A 503A pharmacy compounding semaglutide for a patient must have a valid patient-specific prescription and a documented clinical rationale for why the compounded product is necessary for that specific patient. In practice, this most commonly means documenting the patient's inability to access or afford the branded product, or a documented clinical need for a formulation or dose that is not commercially available.
503B outsourcing facilities are a separate category created by the Drug Quality and Security Act of 2013. They are registered with the FDA, subject to FDA inspection and current Good Manufacturing Practice requirements, and are permitted to compound in larger quantities without patient-specific prescriptions. However, 503B facilities are also subject to greater FDA oversight - including restrictions on which drugs they can compound and under what conditions.
For providers, the key practical distinction is this: a 503B facility that is FDA-registered, inspected, and operating within its legal scope provides a higher level of quality assurance and a more defensible sourcing basis than an unregistered or uninspected 503A pharmacy that is compounding GLP-1s in high volume without adequate quality controls.
EVALUATING A COMPOUNDING PHARMACY BEFORE PRESCRIBING
Before prescribing any compounded medication - including GLP-1 agents - providers have a professional responsibility to exercise due diligence in evaluating the pharmacy from which they are sourcing. This is not a legal technicality. Providers who prescribe compounded medications from pharmacies that are not operating legally or that produce substandard products are potentially liable for patient harm resulting from that prescribing decision.
The following due diligence steps are a minimum standard for evaluating a compounding pharmacy.
Verify licensing and registration. Confirm that the pharmacy holds a valid pharmacy license in the state where it is operating and, where applicable, in the states where it ships medications. For 503B facilities, confirm FDA registration. This information should be readily available from the pharmacy and verifiable through state pharmacy board databases and the FDA's list of registered outsourcing facilities.
Request a certificate of analysis for the specific compound. A certificate of analysis - or CoA - is a document from an independent third-party laboratory confirming the identity, potency, purity, and sterility of a specific batch of compounded medication. Reputable compounding pharmacies provide CoAs on request. A pharmacy that cannot or will not provide a CoA for its compounded GLP-1 products is a significant red flag.
Assess the pharmacy's compliance history. FDA warning letters, state pharmacy board actions, and recall history are all publicly accessible. A pharmacy with a history of quality violations, warning letters for sterility failures, or state board disciplinary actions is not an appropriate source for injectable compounded medications regardless of price or convenience.
Confirm sterility testing for injectable products. Compounded semaglutide and tirzepatide are injectable products. Injectable compounds must be sterile, and sterility failures in compounded injectables have resulted in serious patient harm including infections and deaths in documented cases nationally. Confirming that the pharmacy performs appropriate sterility testing ā€” including USP 71 sterility testing and endotoxin testing - is a non-negotiable quality standard for any injectable compound.
SAFETY CONSIDERATIONS SPECIFIC TO COMPOUNDED GLP-1 PRODUCTS
Beyond the regulatory and sourcing considerations, several safety issues are specific to compounded GLP-1 medications and warrant patient counseling and provider awareness.
Potency variability. Unlike FDA-approved products that must meet standardized potency specifications, compounded products can vary in potency between batches and between pharmacies. A patient who switches between compounded products from different sources - or who receives product from a different batch - may receive a meaningfully different dose than intended. Counseling patients on this variability and monitoring clinical response closely when product sources change is a practical safety measure.
Salt form issues. The FDA has specifically flagged the use of semaglutide sodium and semaglutide acetate - salt forms of semaglutide - in compounded products as a safety concern. These salt forms have different pharmacologic properties than the semaglutide used in branded products and have not been studied for safety and efficacy in humans. Providers should confirm that any compounded semaglutide they prescribe uses the same base compound as the branded product rather than a salt form that has not been clinically validated.
Tirzepatide compounding complexity. Tirzepatide is a more complex molecule than semaglutide and is more technically challenging to compound accurately. The FDA has expressed concerns about the ability of compounding pharmacies to reliably reproduce the complex structure of tirzepatide, and quality variability is a more significant concern with compounded tirzepatide than with compounded semaglutide.
DOCUMENTATION PRACTICES FOR PROVIDERS PRESCRIBING COMPOUNDED GLP-1S
Providers who choose to continue prescribing compounded GLP-1 medications - after carefully evaluating the current legal landscape and their sourcing practices - should ensure that their documentation reflects a defensible, informed prescribing decision.
The patient chart should include the clinical indication for GLP-1 therapy, the documented rationale for using a compounded rather than branded product, confirmation that the patient was informed of the compounded and non-FDA-approved status of the medication, the name and licensing status of the compounding pharmacy, and the patient's informed consent to receive a compounded medication.
For practices that prescribe compounded GLP-1s at volume, having a standardized documentation template that captures all of these elements consistently across every patient chart is both efficient and protective. A single chart note that appears to be a thoughtful, individualized clinical decision is far more defensible than a chart that contains nothing beyond the prescription itself.
STAYING CURRENT AS THE LANDSCAPE EVOLVES
The regulatory environment for compounded GLP-1 medications is not static. FDA guidance, shortage designations, state pharmacy board actions, and federal enforcement priorities all continue to evolve. Providers who made prescribing decisions based on the regulatory environment of eighteen months ago and have not updated their knowledge since are operating on outdated information in a space where the rules are actively changing.
Subscribing to FDA MedWatch alerts, monitoring state pharmacy board communications, and consulting with a healthcare attorney familiar with compounding pharmacy law at least annually are practical steps for staying current. Providers who are members of professional organizations in the metabolic health or integrative medicine space should also monitor those organizations' guidance on compounded GLP-1 prescribing as regulatory developments occur.
BOTTOM LINE
Compounded GLP-1 medications occupy a legal and clinical space that requires active, current knowledge rather than passive assumptions. The regulatory landscape has shifted materially from the shortage period, and providers who continue prescribing compounded GLP-1s owe it to themselves and their patients to understand the current legal basis, to source from pharmacies that meet rigorous quality standards, and to document their prescribing decisions in a way that reflects informed, defensible clinical judgment.
